BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24039090)

  • 1. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
    Goldberg DS; Makar G; Bittermann T; French B
    Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of model for end-stage liver disease exceptions for donation after cardiac death graft recipients relisted for liver transplantation.
    Maduka RC; Abt PL; Goldberg DS
    Liver Transpl; 2015 Apr; 21(4):554-60. PubMed ID: 25597393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
    Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
    J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
    DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
    Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sickest first? Disparities with model for end-stage liver disease-based organ allocation: one region's experience.
    Schaffer RL; Kulkarni S; Harper A; Millis JM; Cronin DC
    Liver Transpl; 2003 Nov; 9(11):1211-5. PubMed ID: 14586883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
    Park SJ; Freise CE; Hirose R; Kerlan RK; Yao FY; Roberts JP; Vagefi PA
    Clin Transplant; 2012; 26(4):E359-64. PubMed ID: 22693962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
    Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
    Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation.
    Vagefi PA; Ascher NL; Freise CE; Dodge JL; Roberts JP
    Liver Transpl; 2012 Feb; 18(2):160-5. PubMed ID: 22006378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model for end-stage liver disease and model for end-stage liver disease-Na scores predict both before-listing and wait-list mortality.
    Yamashiki N; Sugawara Y; Tamura S; Kaneko J; Nojiri K; Aoki T; Sakamoto Y; Hasegawa K; Koike K; Kokudo N
    Transplant Proc; 2012 Mar; 44(2):389-92. PubMed ID: 22410024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
    Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
    Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
    Nobel YR; Goldberg DS
    Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. United Network for Organ Sharing regional variations in appeal denial rates with non-standard Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exceptions: support for a national review board.
    Gish RG; Wong RJ; Honerkamp-Smith G; Xu R; Osorio RW
    Clin Transplant; 2015 Jun; 29(6):513-22. PubMed ID: 25808918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic disparities in deceased donor liver transplantation within a single UNOS region.
    Barshes NR; Becker NS; Washburn WK; Halff GA; Aloia TA; Goss JA
    Liver Transpl; 2007 May; 13(5):747-51. PubMed ID: 17457866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Characteristics of Patients Listed for Liver Transplantation Will Lead to Higher Rates of Waitlist Removal Due to Clinical Deterioration.
    Yi Z; Mayorga ME; Orman ES; Wheeler SB; Hayashi PH; Barritt AS
    Transplantation; 2017 Oct; 101(10):2368-2374. PubMed ID: 28858174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator.
    Díaz LA; Norero B; Lara B; Robles C; Elgueta S; Humeres R; Poniachik J; Silva G; Wolff R; Innocenti F; Rojas JL; Zapata R; Hunter B; Álvarez S; Cancino A; Ibarra J; Rius M; González S; Calabrán L; Pérez RM
    Ann Hepatol; 2019; 18(2):325-330. PubMed ID: 31010794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes in liver transplant recipients with Model for End-stage Liver Disease scores of 40 or higher: a decade-long experience.
    Panchal HJ; Durinka JB; Patterson J; Karipineni F; Ashburn S; Siskind E; Ortiz J
    HPB (Oxford); 2015 Dec; 17(12):1074-84. PubMed ID: 26373873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.
    Mehta N; Dodge JL; Hirose R; Roberts JP; Yao FY
    Am J Transplant; 2019 Aug; 19(8):2210-2218. PubMed ID: 30861298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.